289 related articles for article (PubMed ID: 33279178)
1. Monoclonal antibodies in frontline acute lymphoblastic leukemia.
Chew S; Jammal N; Kantarjian H; Jabbour E
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101226. PubMed ID: 33279178
[TBL] [Abstract][Full Text] [Related]
2. Antibody based therapy in relapsed acute lymphoblastic leukemia.
Jammal N; Chew S; Jabbour E; Kantarjian H
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181
[TBL] [Abstract][Full Text] [Related]
3. Antibody-based therapies in patients with acute lymphoblastic leukemia.
Dinner S; Liedtke M
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):9-15. PubMed ID: 30504286
[TBL] [Abstract][Full Text] [Related]
4. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
[TBL] [Abstract][Full Text] [Related]
5. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
6. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.
Kantarjian H; Jabbour E
Am Soc Clin Oncol Educ Book; 2018 May; 38():574-578. PubMed ID: 30231308
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies in acute lymphoblastic leukemia therapy.
Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
[TBL] [Abstract][Full Text] [Related]
8. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Jabbour EJ; Sasaki K; Ravandi F; Short NJ; Garcia-Manero G; Daver N; Kadia T; Konopleva M; Jain N; Cortes J; Issa GC; Jacob J; Kwari M; Thompson P; Garris R; Pemmaraju N; Yilmaz M; O'Brien SM; Kantarjian HM
Cancer; 2019 Aug; 125(15):2579-2586. PubMed ID: 30985931
[TBL] [Abstract][Full Text] [Related]
9. Loss of CD22 expression and expansion of a CD22
Reinert J; Beitzen-Heineke A; Wethmar K; Stelljes M; Fiedler W; Schwartz S
Ann Hematol; 2021 Nov; 100(11):2727-2732. PubMed ID: 34331563
[TBL] [Abstract][Full Text] [Related]
10. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
Samra B; Jabbour E; Ravandi F; Kantarjian H; Short NJ
J Hematol Oncol; 2020 Jun; 13(1):70. PubMed ID: 32503572
[TBL] [Abstract][Full Text] [Related]
11. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia.
Short NJ; Jabbour E; Jamison T; Paul S; Cuglievan B; McCall D; Gibson A; Jain N; Haddad FG; Nasr LF; Marx KR; Rausch C; Savoy JM; Garris R; Ravandi F; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e168-e173. PubMed ID: 38212207
[TBL] [Abstract][Full Text] [Related]
12. Should immunologic strategies be incorporated into frontline ALL therapy?
Rank CU; Stock W
Best Pract Res Clin Haematol; 2018 Dec; 31(4):367-372. PubMed ID: 30466749
[TBL] [Abstract][Full Text] [Related]
13. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
Wynne J; Wright D; Stock W
Blood Adv; 2019 Jan; 3(1):96-104. PubMed ID: 30622147
[TBL] [Abstract][Full Text] [Related]
14. Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia.
Kegyes D; Jitaru C; Ghiaur G; Ciurea S; Hoelzer D; Tomuleasa C; Gale RP
Blood Rev; 2023 May; 59():101042. PubMed ID: 36732205
[TBL] [Abstract][Full Text] [Related]
15. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
[TBL] [Abstract][Full Text] [Related]
16. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
17. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
[TBL] [Abstract][Full Text] [Related]
18. Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.
Guerra VA; Jabbour EJ; Ravandi F; Kantarjian H; Short NJ
Ther Adv Hematol; 2019; 10():2040620719849496. PubMed ID: 31205644
[TBL] [Abstract][Full Text] [Related]
19. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
Wullenkord R; Reicherts C; Mikesch JH; Marx J; Wethmar K; Albring J; Call S; Lenz G; Stelljes M
Ann Hematol; 2021 Feb; 100(2):587-589. PubMed ID: 32829460
[No Abstract] [Full Text] [Related]
20. Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia.
Ohana Z; Serraes S; Elder C; Katusa N
J Oncol Pharm Pract; 2022 Jul; 28(5):1269-1275. PubMed ID: 35043731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]